AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer patient outcomes, announced that Board Chairman Gabriele Cerrone has purchased 38,000 additional company shares in the open market. This acquisition increases Cerrone's total holdings to 4,910,759 shares.
AccuStem Sciences (OTCQB: ACUT), un'azienda di diagnostica in fase clinica focalizzata sui risultati per i pazienti affetti da cancro, ha annunciato che il presidente del consiglio Gabriele Cerrone ha acquistato 38.000 ulteriori azioni della società sul mercato aperto. Questa acquisizione porta il totale delle partecipazioni di Cerrone a 4.910.759 azioni.
AccuStem Sciences (OTCQB: ACUT), una empresa de diagnóstico en etapa clínica centrada en los resultados de los pacientes con cáncer, anunció que el presidente de la junta Gabriele Cerrone ha comprado 38,000 acciones adicionales de la empresa en el mercado abierto. Esta adquisición aumenta las tenencias totales de Cerrone a 4,910,759 acciones.
AccuStem Sciences (OTCQB: ACUT), 암 환자의 결과에 초점을 맞춘 임상 단계 진단 회사는 이사회 의장 Gabriele Cerrone가 공개 시장에서 38,000주의 추가 주식을 구매했다고 발표했습니다. 이 인수로 Cerrone의 총 보유 주식은 4,910,759주로 증가했습니다.
AccuStem Sciences (OTCQB: ACUT), une entreprise de diagnostic en phase clinique axée sur les résultats des patients atteints de cancer, a annoncé que le président du conseil Gabriele Cerrone a acheté 38 000 actions supplémentaires de la société sur le marché libre. Cette acquisition porte le total des participations de Cerrone à 4 910 759 actions.
AccuStem Sciences (OTCQB: ACUT), ein Unternehmen für klinische Diagnostik, das sich auf die Ergebnisse von Krebspatienten konzentriert, gab bekannt, dass der Vorsitzende des Vorstands Gabriele Cerrone 38.000 zusätzliche Unternehmensaktien auf dem offenen Markt erworben hat. Diese Akquisition erhöht Cerrones Gesamtbestand auf 4.910.759 Aktien.
- Chairman's increased stake demonstrates insider confidence in company
- Significant insider ownership with Chairman holding 4.91M shares
- Trading on OTCQB market indicates lower tier exchange listing
LONDON and PHOENIX, April 10, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 38,000 ACUT shares in the open market. This brings his total holding to 4,910,759 shares.
About AccuStem
AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor “stemness,” we believe our tools will help care teams better understand the biology of each patient’s cancer, leading to more informed decision making. For more information, please visit www.accustem.com.
Investor and Media Contact:
Wendy Blosser
Email: investors@accustem.com
FAQ
How many ACUT shares did AccuStem's Chairman purchase in April 2025?
What is the total number of ACUT shares held by Gabriele Cerrone after the recent purchase?
What exchange is AccuStem Sciences (ACUT) listed on?
What type of company is AccuStem Sciences (ACUT)?
